Merih Kızıl Çakar

Merih Kızıl Çakar

Auto-generated profile, based on publicly available information

Merih Kızıl Çakar

Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 August 2016 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
MDMehmet Sinan Dal
Mehmet Sinan Dal
ETEmre Tekgündüz
Emre Tekgündüz
MÇMerih Kızıl Çakar
Merih Kızıl Çakar
AKAli Hakan Kaya
Ali Hakan Kaya
SNSinem Namdaroğu
Sinem Namdaroğu
FAFevzi Altuntaş
Fevzi Altuntaş

30 April 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
HBHikmettullah Batgi̇
Hikmettullah Batgi̇
SBSemih Başcı
Semih Başcı
MDMehmet Sinan Dal
Mehmet Sinan Dal
MÇMerih Kizil Çakar
Merih Kizil Çakar
BUBahar Uncu Ulu
Bahar Uncu Ulu
FAFevzi Altuntaş
Fevzi Altuntaş
GDP (gemcitabine, dexamethasone and cisplatin) is a well-established salvage regimen for relapsed and refractory lymphomas. In this study, we aimed to share our experience with the patients who received GDP/R-GDP (rituximab-gemcitabine, dexamethasone and cisplatin) for stem cell mobilization. Data of 69 relapsed and refractory Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL) patients who received GDP/R-GDP as salvage chemotherapy in our center between July 2014 and January 2020 were retrospectively evaluated. After the evaluation of response, 52 patients had a chemosensitive disease and underwent mobilization with GDP/R-GDP plus G-CSF (granulocyte colony-stimulating factor). Collected CD34+ stem cells and related parameters were compared in terms of diagnosis of HL and NHL, early and late stage, patients who did not receive RT and those who received RT, and patients aged under 60 and over 60. On the 15th day on average (range 11?20), median 8.7 × 106 /kg (4.1 - 41.5) CD34+ stem cells were collected in 51 (98%) of our 52 chemosensitive patients and 1 (2%) patients failed to mobilize. We observed acceptable hematological and non-hematological toxicity. The targeted amount of 2 × 106 /kg CD34+ stem cells was attained by 98% (n: 51) patients, and all of them underwent autologous stem cell transplantation. Moreover, low toxicity profiles provide outpatient utilization option clinics with close follow-up and adequate supportive care. We suggest that GDP/R-GDP plus G-CSF can be used as an effective chemotherapy regimen for mobilizing CD34+ stem cells from peripheral blood in relapsed and refractory lymphoma patients due to low toxicity, effective tumor reduction, and successful stem cell mobilization. It can also be assumed that the GDP mobilization regimen may be more effective, especially in patients with early-stage disease and in HL patients.

1 November 2021 in Leukemia Research
Verified
Journal Article
Closed access
BUBahar Uncu Ulu
Bahar Uncu Ulu
TYTuğçe Nur Yiğenoğlu
Tuğçe Nur Yiğenoğlu
SBSemih Başcı
Semih Başcı
MBMehmet Bakirtas
Mehmet Bakirtas
DŞDerya Şahin
Derya Şahin
FAFevzi Altuntaş
Fevzi Altuntaş

13 September 2021 in Journal of Chemotherapy
Verified
Journal Article
Closed access
BUBahar Uncu Ulu
Bahar Uncu Ulu
MDMehmet Sinan Dal
Mehmet Sinan Dal
IYIpek Yonal-Hindilerden
Ipek Yonal-Hindilerden
OAOlga Meltem Akay
Olga Meltem Akay
OMOzgur Mehtap
Ozgur Mehtap
FAFevzi Altuntaş
Fevzi Altuntaş
The prognosis is poor for relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) patients. The brentuximab vedotin (Bv) and bendamustine (B) combination has been used as a preferable salvage regimen in R/R cHL patient trials. We retrospectively evaluated response rates, toxicities, and the survival in R/R cHL patients treated with the BvB combination. In a multi-centre real-life study, 61 R/R HL patients received intravenous doses of 1.8 mg/kg Bv on the first day plus 90 mg/m2 B on the first and second days of a 21-day cycle as a second-line or beyond-salvage regimen. Patients’ median age at BvB initiation was 33 (range: 18–76 years). BvB was given as median third-line treatment for a median of four cycles (range: 2–11). The overall and complete response rates were 82% and 68.9%, respectively. After BvB initiation, the median follow-up was 14 months, and one- and two-year overall survival rates were 85% and 72%, respectively. Grade 3/4 toxicities included neutropenia (24.6%), lymphopenia (40%), thrombocytopenia (13%), anaemia (13%), infusion reactions (8.2%), neuropathy (6.5%), and others. The BvB combination could be given as salvage regimen aiming a bridge to autologous stem cell transplant (ASCT), in patients relapse after ASCT or to transplant-ineligible patients with manageable toxicity profiles.

1 June 2020 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
TYTuğçe Nur Yiğenoğlu
Tuğçe Nur Yiğenoğlu
SBSemih Başcı
Semih Başcı
BUBahar Uncu Ulu
Bahar Uncu Ulu
MBMehmet Bakirtas
Mehmet Bakirtas
AKAli Kılınç
Ali Kılınç
FAFevzi Altuntaş
Fevzi Altuntaş